Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc…
| Periodo | 2026-11 | 2026-09 |
|---|---|---|
| Real | — | $-4.88 |
| Estimado | $-0.50 | $-4.71 |
| Sorpresa | — | -3.6% |
| Métrica | ATTO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
Attovia Therapeutics, Inc. cotiza a 13.73 USD y tiene una capitalización bursátil de $627M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud